Corticobasal Degeneration

 

 Buy Article Permissions and Reprints

ABSTRACT

Corticobasal degeneration (CBG) is an increasingly recognized neurodegenerative disease with both motor and cognitive dysfunction. The diagnosis is probably underestimated because of the heterogeneity of clinical features, overlap with symptoms, and pathologic findings of other neurodegenerative diseases. The most characteristic initial motor symptoms are akinesia, rigidity, and apraxia. Dystonia and alien limb phenomena are frequently observed. There is often a parkinsonian picture with failure or lack of efficacy of dopaminergic medical therapy. Cognitive decline, prompting the diagnosis of dementia, may be the most common presentation of CBD that is misdiagnosed. Pathology is characterized by an asymmetric frontoparietal neuronal loss and gliosis with ballooned, achromatic cortical neurons, nigral degeneration, and variable subcortical involvement. Neuroimaging and electrophysiologic studies may help with the diagnosis but are not specific. Treatment is primarily symptomatic and minimally effective, especially after the first several years of symptoms. CBD should be considered in the differential diagnosis of patients with motor and cognitive dysfunction presenting with cortical and subcortical features. Further studies to elucidate molecular abnormalities and biological markers associated with CBD are needed to improve clinical diagnosis and treatment of patients with this disorder.

REFERENCES

• 1 Rebeiz J J, Kolodny E H, Richardson E P. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life.  Trans Am Neurol Assoc . 1967;  92 23-26
  PubMedGoogle Scholar
• 2 Rebeiz J J, Kolodny E H, Richardson E P. Corticodentatonigral degeneration with neuronal achromasia.  Arch Neurol . 1968;  18 20-33
  CrossrefPubMedGoogle Scholar
• 3 Wenning G K, Litvan I, Jankovic J. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination.  J Neurol Neurosurg Psychiatry . 1998;  64 184-189
  CrossrefPubMedGoogle Scholar
• 4 Rinne J O, Lee M S, Thompson P D, Marsden C D. Corticobasal degeneration: a clinical study of 36 cases.  Brain . 1994;  117 1183-1196
  CrossrefPubMedGoogle Scholar
• 5 Watts R L, Mirra S S, Richardson E P. Corticobasal ganglionic degeneration. In: Marsden CD, Fahn S, eds. Movement Disorders 3 London: Butterworth 1994: 282-299
  Google Scholar
• 6 Schneider J A, Watts R L, Gearing M, Brewer R P, Mirra S S. Corticobasal degeneration: neuropathological and clinical heterogeneity.  Neurology . 1997;  48 959-969
  CrossrefPubMedGoogle Scholar
• 7 Watts R, Brewer R P, Schneider J A, Mirra S S. Corticobasal degeneration. In: Watts RL, Koller WC, eds. Movement Disorders: Neurologic Principles and Practice New York: McGraw Hill 1997: 611-621
  Google Scholar
• 8 Di Maria E, Tabaton M, Vigo T. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy.  Ann Neurol . 2000;  47 374-377
  CrossrefPubMedGoogle Scholar
• 9 Riley D, Lang A. Corticobasal degeneration. Clinical diagnostic criteria.  Adv Neurol . 2000;  82 29-34
  PubMedGoogle Scholar
• 10 Grimes D A, Lang A E, Bergeron C B. Dementia as the most common presentation of cortical-basal ganglionic degeneration.  Neurology . 1999;  53 1969-1974
  CrossrefPubMedGoogle Scholar
• 11 Thompson P D, Shibasaki H. Corticobasal degeneration. Myoclonus in corticobasal degeneration and other neurodegenerations.  Adv Neurol . 2000;  82 69-81
  PubMedGoogle Scholar
• 12 Vanek Z F, Jankovic J. Corticobasal degeneration. Dystonia in corticobasal degeneration.  Adv Neurol . 2000;  82 61-67
  PubMedGoogle Scholar
• 13 Litvan I, Agid Y, Goetz C. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study.  Neurology . 1997;  48 119-125
  CrossrefPubMedGoogle Scholar
• 14 Kumar R, Bergeron C, Pollanen M S, Lang A E. Cortical basal ganglionic degeneration. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders Baltimore: Williams & Wilkins 1998: 297-316
  Google Scholar
• 15 Rivaud-Pechoux S, Vidailhet M, Gallouedec G, Litvan I, Gaymard B, Pierrot-Deseilligny C. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy.  Neurology . 2000;  54 1029-1032
  PubMedGoogle Scholar
• 16 Litvan I, Agid Y, Jankovic J. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome).  Neurology . 1996;  46 922-930
  CrossrefPubMedGoogle Scholar
• 17 Vidailhet M, Rivaud-Pechoux S. Corticobasal degeneration: eye movement disorders in corticobasal degeneration.  Adv Neurol . 2000;  82 161-167
  PubMedGoogle Scholar
• 18 Leiguarda R, Lees A J, Merello M, Starkstein S, Marsden C D. The nature of apraxia in corticobasal degeneration.  J Neurol Neurosurg Psychiatry . 1994;  57 455-459
  CrossrefPubMedGoogle Scholar
• 19 Otsuki M, Soma Y, Yoshimura N, Tsuji S. Slowly progressive limb-kinetic apraxia.  Eur Neurol . 1997;  37 100-103
  PubMedGoogle Scholar
• 20 Pillon B, Blin J, Vidailhet M. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer's disease.  Neurology . 1995;  45 1477-1483
  CrossrefPubMedGoogle Scholar
• 21 Lerner A, Friedland R, Riley D. Dementia with pathological findings of corticobasal ganglionic degeneration.  Ann Neurol . 1992;  32 271
  PubMedGoogle Scholar
• 22 Cummings J L, Litvan I. Corticobasal degeneration: neuropsychiatric aspects of corticobasal degeneration.  Adv Neurol . 2000;  82 147-152
  PubMedGoogle Scholar
• 23 Watts R L, William R S, Growdon J H. Corticobasal ganglionic degeneration.  Neurology . 1985;  178 (178)
  PubMedGoogle Scholar
• 24 Savoiardo M, Grisoli M, Girotti F. Corticobasal degeneration: magnetic resonance imaging in CBD, related atypical parkinsonian disorders, and dementias.  Adv Neurol . 2000;  82 197-208
  PubMedGoogle Scholar
• 25 Yamauchi H, Fukuyama H, Nagahama Y. Atrophy of the corpus callosum, cortical hypometabolism, and cognitive impairment in corticobasal degeneration.  Arch Neurol . 1998;  55 609-614
  CrossrefPubMedGoogle Scholar
• 26 Schrag A, Good C D, Miszkiel K. Differentiation of atypical parkinsonian syndromes with routine MRI.  Neurology . 2000;  54 697-702
  CrossrefPubMedGoogle Scholar
• 27 Brooks D J. Corticobasal degeneration: functional imaging studies in corticobasal degeneration.  Adv Neurol . 2000;  82 209-215
  PubMedGoogle Scholar
• 28 Okuda B, Tachibana H, Kawabata K, Takeda M, Sugita M. Cerebral blood flow correlates of higher brain dysfunctions in corticobasal degeneration.  J Geriatr Psychiatry Neurol . 1999;  12 189-193
  PubMedGoogle Scholar
• 29 Laureys S, Salmon E, Garraux G. Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration.  J Neurol . 1999;  246 1151-1158
  CrossrefPubMedGoogle Scholar
• 30 Sawle G V, Brooks D J, Marsden C D, Frackowiak R S. Corticobasal degeneration: a unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography.  Brain . 1991;  114 541-556
  CrossrefPubMedGoogle Scholar
• 31 Nagasawa H, Tanji H, Nomura H. PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration.  J Neurol Sci . 1996;  139 210-217
  CrossrefPubMedGoogle Scholar
• 32 Takeda M, Tachibana H, Okuda B, Kawabata K, Sugita M. Electrophysiological comparison between corticobasal degeneration and progressive supranuclear palsy.  Clin Neurol Neurosurg . 1998;  100 94-98
  CrossrefPubMedGoogle Scholar
• 33 Okuda B, Tachibana H, Takeda M, Kawabata K, Sugita M. Asymmetric changes in somatosensory evoked potentials correlate with limb apraxia in corticobasal degeneration.  Acta Neurol Scand . 1998;  97 409-412
  PubMedGoogle Scholar
• 34 Homma A, Harayama H, Kondo H. P300 findings in patients with corticobasal degeneration.  Brain Nerve . 1996;  48 925-929
  PubMedGoogle Scholar
• 35 Watts R L, Mirra S S, Young R R. Corticobasal ganglionic degeneration (CBD) with neuronal achromasia: clinical pathological study of two cases.  Neurology . 1989;  140 (140)
  PubMedGoogle Scholar
• 36 Smith T W, Lippa C F, de Girolama U. Immunocytochemical study of ballooned neurons in cortical degeneration with neuronal achromasia.  Clin Neuropathol . 1992;  11 28-35
  PubMedGoogle Scholar
• 37 Dickson D W. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration.  J Neurol . 1999;  II6-II15 (II6-II15)
  PubMedGoogle Scholar
• 38 Gearing M, Olson D A, Watts R L, Mirra S S. Progressive supranuclear palsy: neuropathologic and clinical heterogeneity.  Neurology . 1994;  44 1015-1024
  PubMedGoogle Scholar
• 39 Delacourte A, Buee L. Normal and pathological tau proteins as factors for microtubule assembly.  Int Rev Cytol . 1997;  171 167-224
  PubMedGoogle Scholar
• 40 Feany M B, Dickson D. Neurodegenerative disorders with extensive tau pathology: a comparative study and review.  Ann Neurol . 1996;  40 139-148
  CrossrefPubMedGoogle Scholar
• 41 Steele J C, Richardson J C, Olszewski J. Progressive supranuclear palsy.  Arch Neurol . 1964;  10 333-359
  CrossrefPubMedGoogle Scholar
• 42 Litvan I. Recent advances in atypical parkinsonian disorders.  Curr Opin Neurol . 1999;  12 441-446
  CrossrefPubMedGoogle Scholar
• 43 Adams R D, Van Bogaert L, Vander Eecken H. Striatonigral degeneration.  J Neuropathol Exp Neurol . 1964;  23 584-608
  PubMedGoogle Scholar
• 44 Takei Y, Mirra S S. Striatonigral degeneration: a form of multiple system atrophy with clinical parkinsonism.  Prog Neuropathol . 1973;  2 217-251
  PubMedGoogle Scholar
• 45 Spokes E GS, Bannister R, Oppenheimer D R. Multiple system atrophy with autonomic failure.  J Neurol Sci . 1979;  43 59-82
  CrossrefPubMedGoogle Scholar
• 46 Wenning G K, Ben Shlomo Y, Magalhaes M, Daniel S E, Quinn N P. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases.  Brain . 1994;  117 835-845
  CrossrefPubMedGoogle Scholar
• 47 Jendroska K, Rossor M N, Mathias C J, Daniel S E. Morphological overlap between corticobasal degeneration and Pick's disease: a clinicopathological report.  Mov Disord . 1995;  10 111-114
  CrossrefPubMedGoogle Scholar
• 48 Lang A E, Bergeron C, Pollanen M S, Ashby P. Parietal Pick's disease mimicking cortical-basal ganglionic degeneration.  Neurology . 1994;  44 1436-1440
  CrossrefPubMedGoogle Scholar
• 49 Cole M, Wright D, Banker B Q. Familial aphasia due to Pick's disease.  Ann Neurol . 1979;  6 158
  PubMedGoogle Scholar
• 50 Wojcieszek J, Lang A E, Jankovic J, Greene P, Deek J. Case 1: rapidly progressive aphasia, apraxia, dementia, myoclonus and parkinsonism.  Mov Disord . 1994;  9 358-366
  CrossrefPubMedGoogle Scholar
• 51 Ball JA., Lantos P L, Jackson M. Alien hand sign in association with Alzheimer's histopathology.  J Neurol Neurosurg Psychiatry . 1993;  56 1020-1023
  PubMedGoogle Scholar
• 52 Hirano A, Kurland L T, Krooth R S. Parkinsonism-dementia complex, an endemic disease on the Island of Guam: I. Clinical features.  Brain . 1961;  84 642-661
  CrossrefPubMedGoogle Scholar
• 53 Hirano A, Malamud M, Kurland L T. Parkinsonismdementia complex on the Island of Guam: II. Pathological features.  Brain . 1961;  84 662-679
  CrossrefPubMedGoogle Scholar
• 54 Cannard K R, Galvez-Jimenez N, Watts R L. Creutzfeldt-Jakob disease presenting and evolving as rapidly progressive corticobasal degeneration.  Neurology . 1998;  50 A95
  PubMedGoogle Scholar
• 55 Kompoliti K, Goetz C G, Boeve B F. Clinical presentation and pharmacological therapy in corticobasal degeneration.  Arch Neurol . 1998;  55 957-961
  CrossrefPubMedGoogle Scholar
• 56 Fazzini E, Dogali M, Beric A. The effects of unilateral ventral posterior medial pallidotomy in patients with Parkinson's disease and Parkinson's plus syndromes. In: Koller WC, Paulson G, eds. Therapy of Parkinson's Disease New York: Marcel Dekker 1995: 353-379
  Google Scholar